LCE publishes a range of reports covering key issues on the diagnosis, treatment and care of lymphomas and CLL in Europe, highlighting gaps or discrepancies in lymphoma healthcare policy and practice and making recommendations for improvement.
LCE publications are aimed at all those with an interest in improving outcomes in lymphoma and can be used by patient/care advocacy organisations to support the case for change in their countries.
People diagnosed with lymphoma in Europe do not all receive the same high standard of treatment and care that they deserve. LCE’s Lymphoma Care in Europe report examines the extent of those differences and disparities, covering therapy regulation and access, clinical trials and patient/carer experience. Drawing on the Coalition’s library and database of resources, data from its Global Patient Survey and a range of other recognised sources, the report provides a revealing overview of the situation facing people with lymphoma throughout Europe, before concluding with a comprehensive set of findings and recommendations.
The Hodgkin Lymphoma report provides all those working in the field of lymphoma and patient/carer support with a thorough introduction to the main features and presentation of this subtype. With its twin peaks of incidence in younger and older people, Hodgkin lymphoma is unusual in the field of cancer and thus has a number of particular issues in relation to its diagnosis, treatment and aftercare. The report examines current standards of care across Europe, highlighting areas of inequality in access to therapies and clinical trials, along with key insights from patient experience data. Although a disease with a high cure rate, the report identifies matters for further development and improvement.
Despite its name, chronic lymphocytic leukaemia is a form of lymphoma and a chronic one with a higher incidence and prevalence in older people. Often diagnosed by chance through routine blood tests, there are a host of psycho-social and support issues associated with CLL, not least due to the treatment protocol of “watch and wait” and its incurable nature. The CLL report provides all those working with lymphoma and leukaemia patients in Europe with a detailed review of care and treatment practice, along with an analysis of current therapy and clinical trial access. Detailed patient experience data roots the report in the lived experience of CLL before it concludes with a clear summary of the European situation and the steps that need to be taken next.